| |
Group A(n=20) |
Group E (n=20) |
Group N (n=20) |
p value |
| Mephentermine used |
1 (5%) |
1 (5%) |
12 (60%) |
0.01* |
| Bradycardia |
0 |
0 |
8 (40%) |
0.01* |
| Tachycardia |
1 (5%) |
0 (0%) |
0 (0%) |
0.48 |
| Other adverse effects |
0 |
0 |
0 |
|
| Data described as number (percentage); *p<0.05 considered statistically significant. |
|
